🧪Trial version — For internal lab review only. Not for clinical or production use.
VaxIQ/Hepatitis B
← Back to VaxIQ

Hepatitis B

Hepatitis B Vaccine (HBV)

Tier 1 · EPI/CoreVaccineCuration in progress

Platform: Recombinant protein subunit

Vaccine that protects against hepatitis B virus infection and its long-term complications, including cirrhosis and liver cancer.

anti-HBscorrelate of protectionmemory B cellpediatric

PubMed References

PMID 23249904Schoenberger. Long-term protection hepatitis B vaccination meta-analysis. Pediatr Infect Dis J 2013.

Immunology Sections

Curated section analysis in progress

Structured immunology sections — mechanism, immune response, molecular signatures, correlates of protection, and more — are being prepared by the Precision Vaccines Program team. In the meantime, verified references and live literature from PubMed, Semantic Scholar, and Wikipedia are available below.

MechanismImmune ResponseMolecular & Immune SignaturesCorrelates of ProtectionOpen QuestionsImmunogenicitySafetyInfection Immunology

Verified References

PMID 23249904Schoenberger. Long-term protection hepatitis B vaccination meta-analysis. Pediatr Infect Dis J 2013.

Wikipedia Overview

Full article ↗
Hepatitis B vaccine

Hepatitis B vaccine is a vaccine that prevents hepatitis B. The first dose is recommended within 24 hours of birth with either two or three more doses given after that. The vaccine is also recommended to premature infants and people with poor immune function such as from HIV/AIDS. It is also recommended that health-care workers be vaccinated. In healthy people, routine immunization results in more than 95% of people being protected.

PubMed Literature

Search PubMed ↗

No PubMed results retrieved.

Semantic Scholar

Search S2 ↗

No Semantic Scholar results retrieved.